Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Semex Alliance has 1 pending office action in Biotechnology & Pharmaceuticals. The portfolio has 1 distinct examiner and 1 distinct art unit. GU, QINHUA is the busiest examiner, with 1 pending matter, making the pending prosecution activity dependent on one examination channel.
The narrow assignment supports direct docket management and a response tailored to the examiner’s treatment of the biotechnology or pharmaceutical subject matter. Counsel should align claim language with the specification before addressing the action, because there is no separate examiner or art-unit pattern in the available data to support a broader portfolio strategy. An examiner interview may also be evaluated as a practical way to clarify the next prosecution step.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GU, QINHUA | 1 | 76.2% | +27.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709061 | DERIVATION OF NAÏVE BOVINE EMBRYONIC STEM CELLS | GU, QINHUA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709061 | DERIVATION OF NAÏVE BOVINE EMBRYONIC STEM CELLS | GU, QINHUA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709061 | DERIVATION OF NAÏVE BOVINE EMBRYONIC STEM CELLS | GU, QINHUA | 1633 | §103§112 | Non-Final OA | — | Pending | May 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Semex Alliance has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Qinhua Gu has the most, with 1 of The Semex Alliance's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
